Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Plegridy Satisfaction Study in Participants (PLATINUM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02587065
Recruitment Status : Completed
First Posted : October 27, 2015
Results First Posted : January 13, 2020
Last Update Posted : January 13, 2020
Sponsor:
Information provided by (Responsible Party):
Biogen

Brief Summary:
The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as measured by the Abbreviated Treatment Satisfaction Questionnaire to Medication (TSQM-9), at 12 weeks. The secondary objectives of this study are to evaluate in this study population: effects of Peg-IFN beta-1a treatment on participants' satisfaction at 24 weeks; effects of Peg-IFN beta-1a treatment on short-term participants' adherence; effects of Peg-IFN beta-1a treatment on participants' fatigue; effects of Peg-IFN beta-1a on disease activity and physical disability; impact of Peg-IFN beta-1a treatment on participant-reported health-related quality of life; impact of Peg-IFN beta-1a treatment on participants' injection-system satisfaction; Evaluate the relationship between participants' satisfaction and adherence; Evaluate the relationship between participants' satisfaction and social-demographic factors (age, sex, employment working, level of education, etc) and clinical characteristics (annualized relapse rate [ARR], disability, etc.) and to evaluate the treatment safety and tolerability.

Condition or disease Intervention/treatment Phase
Relapsing-Remitting Multiple Sclerosis (RRMS) Drug: peginterferon beta-1a Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 193 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM)
Actual Study Start Date : February 3, 2016
Actual Primary Completion Date : October 2, 2017
Actual Study Completion Date : December 21, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: peginterferon beta-1a
125 μg administered subcutaneously (SC) every 2 weeks
Drug: peginterferon beta-1a
125 mcg administered subcutaneously (SC) every 2 weeks.
Other Names:
  • BIIB017
  • PEGylated Interferon Beta-1a
  • Plegridy
  • PEG IFN β-1a




Primary Outcome Measures :
  1. Change From Baseline in Convenience Satisfaction Score of Treatment Satisfaction Questionnaire to Medication (TSQM-9) at Week 12 [ Time Frame: Baseline, Week 12 ]
    TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Questionnaires were completed electronically by participants, by means of a participant i-PAD at each study visit.


Secondary Outcome Measures :
  1. Change From Baseline in the Score of All Domains of TSQM-9 at Week 24 [ Time Frame: Baseline, Week 24 ]
    TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Questionnaires were completed electronically by participants, by means of a participant i-PAD at each study visit.

  2. Change From Baseline in Number of Participants With Adherence to Study Treatment at Weeks 12 and 24 [ Time Frame: Baseline, Weeks 12 and 24 ]
    Adherence to treatment was evaluated using a questionnaire assessing adherence and the reasons for not taking drug at the recommended frequency of administration. Participants who had taken the prescribed doses of treatment in the previous 28 days were evaluated.

  3. Change From Baseline in Fatigue Status Scale (FSS) Score at Weeks 12 and 24 [ Time Frame: Baseline, Weeks 12 and 24 ]
    FSS is a questionnaire composed of nine statements on the state of fatigue experienced during the previous week. The answers are within a scale of agreement ranging from 1 to 7, where 1 represents less fatigue and 7 indicates highest fatigue. The total score was obtained summing the number given at each item and it ranges from 7 to 63. An overall score of ≥36 indicates a state of fatigue. Questionnaires were completed electronically by participants, by means of a participant i-PAD at each study visit. Here, negative values indicate improvement in FSS score from baseline.

  4. Change From Baseline in Adapted Sclerosis Treatment Concerns Questionnaire (MSTCQ) Score at Weeks 12 and 24 [ Time Frame: Baseline, Weeks 12 and 24 ]
    MSTCQ is a 20-item questionnaire adapted for 'Peg-interferon Beta 1a' containing two domains: injection system satisfaction (1-9) and side effects (1-11). All questions in the MSTCQ have a five-point response choice, with a minimum possible total score of 20 and a maximum possible total score of 100. Lower total scores indicating better outcomes. Questionnaires were completed electronically by participants, by means of a participant I-PAD at each study visit. Here, negative values indicate improvement in MSTCQ score from baseline.

  5. Change From Baseline in Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) Score at Week 12 and 24 [ Time Frame: Baseline, Weeks 12 and 24 ]
    MusiQoL is a self-administered questionnaire consisting of 31 items describing nine dimensions of health-related quality of life (QoL): activities of daily living, psychological wellbeing, symptoms, relationship with friends, relationship with family, sentimental and sexual life, coping rejection, relationship with healthcare system). All items are scored based on frequency/extent of an event on a five-point scale ranging from never/not at all (option 1) to always/very much (option 5). Total score is obtained by linearly transforming and standardizing on a 0-100 scale. Higher scores indicate a better level of health-related QoL for each dimension and for the global index score. Here, negative values indicate improvement in MusiQoL score from baseline.

  6. Change From Baseline in Annualized Relapse Rate (ARR) at Week 24 [ Time Frame: Baseline, Week 24 ]
    Relapses are defined as neurologic symptoms lasting more than 24 hours which occur at least 30 days after the onset of a preceding event. ARR was calculated as the total number of relapses for all participants divided by the total participant-years of exposure to that treatment. Here negative sign indicates decrease in annual relapse rate as compared to baseline.

  7. Percent Change in Relapse-Free Participants at Week 24 [ Time Frame: Baseline, Week 24 ]
    Relapses are defined as neurologic symptoms lasting more than 24 hours which occur at least 30 days after the onset of a preceding event. Percent change in relapse-free participants had been calculated with respect to the number of relapse-free participants at baseline. Here, negative sign indicates decrease in number of relapse free participants at specified timepoint as compared to baseline.

  8. Number of Participants With Adverse Events (AE) [ Time Frame: Baseline up to Week 24 ]
    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can herefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

  9. Number of Participants With AE Stratified by Severity [ Time Frame: Baseline up to Week 24 ]
    Severity of AEs was evaluated based on the following criteria- Mild: Symptoms barely noticeable to participant or does not make participant uncomfortable; does not influence performance or functioning; prescription drug not ordinarily needed for relief of symptom(s) but may be given because of personality of participant. Moderate: Symptoms of a sufficient severity to make participant uncomfortable; performance of daily activity is influenced; participant is able to continue in study; treatment for symptom(s) may be needed. Severe: Symptoms cause severe discomfort; symptoms cause incapacitation or significant impact on participant's daily life; severity may cause cessation of treatment with study treatment; treatment for symptom(s) may be given and/or participant hospitalized.

  10. Number of Participants With Clinical Abnormal Laboratory Values [ Time Frame: Baseline up to Week 24 ]
    Participants with clinical abnormal laboratory values were reported throughout the studies.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Subjects diagnosed with Relapsing Remitting MS according to 2010 McDonald criteria.
  • Subjects with EDSS score between 0.0 and 5.0 at baseline.

Key Exclusion Criteria:

  • Pregnancy or breast-feeding.
  • Have any contra-indications to treatment with Peg-IFN-beta 1a according to the Summary of Product Characteristics.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02587065


Locations
Layout table for location information
Italy
Research Site
Arezzo, Italy, 52100
Research Site
Bari, Italy, 70124
Research Site
Cagliari, Italy, 09126
Research Site
Cefalù, Italy, 90015
Research Site
Chieti, Italy, 66100
Research Site
Como, Italy, 22100
Research Site
Fidenza, Italy, 43036
Research Site
Foligno, Italy, 06034
Research Site
Gallarate, Italy, 21013
Research Site
Genova, Italy, 16132
Research Site
L'Aquila, Italy, 67100
Research Site
Messina, Italy, 98125
Research Site
Milano, Italy, 20132
Research Site
Milano, Italy, 20133
Research Site
Modena, Italy, 41126
Research Site
Mondovì, Italy, 12084
research Site
Napoli, Italy, 80131
Research Site
Napoli, Italy, 80137
Research Site
Orbassano, Italy, 10043
Research Site
Ozieri, Italy, 07014
Research Site
Palermo, Italy, 90129
Research Site
Palermo, Italy, 90146
Research Site
Pavia, Italy, 27100
Research Site
Pietra Ligure, Italy, 17027
Research Site
Pozzilli, Italy, 86077
Research Site
Reggio Calabria, Italy, 89100
Research Site
Roma, Italy, 00152
Research Site
Roma, Italy, 00168
Research Site
Roma, Italy, 00189
Research Site
Torino, Italy, 10126
Sponsors and Collaborators
Biogen
Investigators
Layout table for investigator information
Study Director: Medical Director Biogen
  Study Documents (Full-Text)

Documents provided by Biogen:
Statistical Analysis Plan  [PDF] May 3, 2018
Study Protocol  [PDF] July 28, 2015

Layout table for additonal information
Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT02587065    
Other Study ID Numbers: ITA-PEG-14-10779
2015-002201-11 ( EudraCT Number )
First Posted: October 27, 2015    Key Record Dates
Results First Posted: January 13, 2020
Last Update Posted: January 13, 2020
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Interferons
Interferon-beta
Interferon beta-1a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic